Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism
Status:
Withdrawn
Trial end date:
2021-08-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of an investigational drug, PF-05221304
(PF'1304) on the way the liver handles fat. The planned study will identify why the fat in
the blood increases at the same time this drug reduces fat in the liver. The study will have
two treatment periods of 6 weeks each, separated by a 3 week rest period with no treatment.
The subjects will receive the active drug in one of the 6 week treatment periods and a
placebo in the other 6 week period. The investigators will know when the subjects are
receiving active treatment or placebo, but the subject will not know.